We wanted to evaluate factors associated with high costs after allogeneic haematopoietic SCT (HSCT). We collected all in-patient and outpatient costs during the first year after HSCT over 5 years, from 2003 to 2007. Mean 1-year costs per patient were h141 493 (95% confidence interval (95% CI) ¼ 125 019-157 967). Patients treated with non-myeloablative conditioning (NMC) had reduced costs, but patients treated with reduced-intensity or myeloablative conditioning had similar 1-year costs. Multivariate analysis showed that increased 1-year costs were seen in post-transplant complications: rejection (relative hazard (RH) 1.24, Po0.001), acute GVHD of grades III-IV (1.31, Po0.001) and invasive fungal infection (1.15, P ¼ 0.02). In addition, increased costs were associated with retransplantation (1.21, P ¼ 0.001), mesenchymal stem-cell therapy (1.26, Po0.001), unrelated donor transplants (1.20, P ¼ 0.002) and the need for G-CSF treatment due to poor engraftment (1.12, P ¼ 0.047). In patients without any of these risk factors, mean 1-year costs were h84 773 (95% CI ¼ 71 145-98 400) (n ¼ 51). With three risk factors, the cost increased to h249 775 (95% CI ¼ 166 824-332 727) (n ¼ 14). To conclude, major complications increased the costs of HSCT. Unrelated donor transplants were more expensive than HLAidentical sibling transplants. Costs were reduced in patients treated with NMC.
Introduction
Allogeneic haematopoietic SCT (HSCT) is an expensive therapy. 1 The reasons are that HSCT is highly specialised, labour intensive in terms of use of staff, requires isolation of the patient and has a high requirement for blood products and expensive medication. The costs to health-care systems have steadily increased over the past decades. 2 Thus, in hospitals and in society as a whole, there is much interest in how to reduce costs by making treatments more efficient, by avoiding expensive investigations and medication. In HSCT, there have been large numbers of investigations and publications ranging from basic science to clinical trials. Despite the intensive research in the field and high cost of the procedure, there have been very few investigations and publications on the cost of HSCT. [3] [4] [5] [6] [7] We have previously reported the total costs over 5 years after HSCT in 93 patients transplanted in 1998 and 1999 at our unit. 8 We found that higher costs of HSCT were associated with acute leukaemia, G-CSF prophylaxis, hospital care as opposed to home care, myeloablative conditioning (MAC) as opposed to reduced-intensity conditioning (RIC) and major transplantrelated complications. Owing to increasing costs and limited resources in health care, we decided to perform a new, more modern evaluation. In this study, we looked at the costs over 5 years, from 2003 to 2007. As most of the costs of HSCT occur during the first year, we calculated 1-year costs. We also wanted to evaluate factors associated with high costs after HSCT. In addition, as RIC is being increasingly used, we wanted to compare costs using RIC, MAC and nonmyeloablative conditioning (NMC).
Patients and methods

Between 1 January 2003 and 31 December 2007, 343
HSCTs were performed on 327 patients (20 re-transplantations) at CAST (Centre for Allogeneic Stem Cell Transplantation) (Karolinska University Hospital, Stockholm, Sweden). A total of 125 patients came from other countries and were excluded because the 1-year costs for these patients could not be determined. The characteristics of the 202 patients included in the study are given in Table 1 . Acute leukaemia was the most common diagnosis, and was seen in 76 patients. Patients with non-malignant disorders included patients with severe aplastic anaemia (n ¼ 4), Fanconi's anaemia (n ¼ 3) and inborn errors of metabolism (n ¼ 20). Of the patients with malignancies, 57 were in first remission or in the first chronic phase, and 98 were at more advanced stages of their disease. The majority of patients (63%) received their HSCT graft from an unrelated donor. As an alternative to hospital care, home care is offered to all patients living within 1-2 h driving distance from the hospital, irrespective of donor, conditioning or source of stem cells. The home-care procedure has been published previously in detail. 9 In this analysis, 52 (26%) of the patients were treated at home during the pancytopenic phase. We stopped using G-CSF after HSCT when we found that it was associated with an increased risk of acute GVHD. 10, 11 In this study, G-CSF was given to 23 patients (11%) with delayed and/or poor engraftment. All patients in the study were treated at CAST or at home, and taken care of by nurses and physicians from our unit. After discharge from hospital, patients were followed up twice weekly for 3 months at the outpatient clinic of the Department of Hematology or the Department of Paediatrics. After 3 months, outpatient check-ups were less frequent. After 3 months, patients who came from other parts of Sweden were followed up alternately at the local hospital and at the Karolinska University Hospital. Costs from the other hospitals were not included in this report. However, all patients were routinely examined at the Karolinska University Hospital 6, 9 and 12 months after HSCT.
Donors and conditioning
The donors included one syngeneic twin, 73 HLA-identical sibling donors (36%), 95 HLA-A, HLA-B and HLADRb1-identical so-called matched unrelated donors (MUDs) (47%) and 33 mismatched unrelated donors (16%). Genomic HLA typing was performed in all recipients and donors.
12 G-CSF-mobilised PBSCs were given to 68%. 13 BM was used in 22% of the patients and cord blood in 10% (Table 1) .
Myeloablative conditioning including CY (60 mg/kg) over two consecutive days combined with fractionated TBI (3Gy on four consecutive days) was given to 30 patients. 13 BU combined with CY was administered to 47 (23%) of the patients. RIC, Fludarabine combined with BU, TBI (2 or 6Gy) or CY was administered to 122 (60%) of the patients.
14,15
Immunosuppression Pre-transplant thymoglobulin (ATG, Genzyme, Cambridge, MN, USA) was administered to recipients of unrelated or HLA-mismatched grafts and to all patients with non-malignant disorders, regardless of the type of donor (n ¼ 157, 78%). 16 As immunosuppression, the vast majority received CsA combined with four doses of MTX. 17, 18 Other immunosuppressive protocols consisted of CsA combined with prednisolone administered to recipients of cord blood transplants (n ¼ 20), CsA combined with mycophenolate mofetil and tacrolimus combined with sirolimus.
Supportive care
Patients were treated in the hospital in conventional single rooms with reversed isolation. They were allowed to have a relative or a friend to stay with them. Co-trimoxazol was administered as prophylaxis against pneumocystis during conditioning and until 2 days before HSCT, and the ANC was 40.5 Â 10 9 /L after HSCT. Co-trimoxazol was continued for 6 months and for longer periods in patients with chronic GVHD. Patients with a HSV titre 410 000, determined by ELISA received oral or i.v. acyclovir as prophylaxis from the time of conditioning until the ANC was 40.5 Â 10 9 /L for two consecutive days. Patients with fever 438.5 1C during the pancytopenic phase administered given broad-spectrum antibiotics until ANC was 40.5 Â 10 9 /L. Details regarding treatment were previously reported in detail. 19 MSCs were given to 24 patients as treatment for steroidresistant acute GVHD (n ¼ 9), haemorrhagic cystitis (HC) (n ¼ 7) or as support at the time of SCT, cord blood transplantation or re-transplantation (n ¼ 8). [20] [21] [22] 
Costs
Two methods of calculation of costs were used. We used the so-called cost per patient (CPP) system of in-patients at our hospital. We also calculated the reimbursement system of Stockholm together with the diagnosis-related group (DRG) system/KÖ KS system, which is based on self-costs for the patient and used to calculate the costs of all outpatients at our hospital. In addition, we calculated total parenteral nutrition and the costs for expensive medications, such as anti-fungals, monoclonal antibodies, ATG, etc., for each patient. By adding these three, we could calculate a CPP as reported here. The Department of Auditing at the Karolinska University Hospital used the CPP system, giving a summary of all costs for each patient while in hospital. The CPP system includes all real costs for each patient, such as laboratory work, transfusions, intensive care, radiography, food and anaesthesia. On the ward, patients are assumed to cost a specific amount, which is estimated depending on the diagnosis, the staff, medication, the ward to which they have been assigned and the length of stay. All patients treated at CAST had the same estimated basic costs per day, which were added to the real costs calculated above and included in the CPP system. As total parenteral nutrition and expensive medications cannot be estimated yet in the CPP system, these real costs were also calculated for all individual patients in the study. Using unrelated donors, the real costs of collection and transport of stem cells, and of using a donor were also included in the CPP system. The cost of finding a donor, if initiated by the home hospital before HSCT, was not included.
The second method of cost calculation was that by which the hospital is reimbursed in Stockholm. This is a DRG system with a price list based on self-costs. The clinics are reimbursed in the same way for their outpatients, but this system is called 'KÖ KS'. The DRG and KÖ KS costs are estimated and calculated by the 'top-down' method. Data from the hospitals' Auditing Departments are collected and classified according to instructions about how to reduce costs. All costs are entered into the DRG in-patient system and the KÖ KS outpatient system. Salaries for the staff and routine medications are examples of costs that were entered. Expensive medications such as anti-fungals, ATG, broad-spectrum antibiotics, total parenteral nutrition and i.v. g-globulin were added on top for each patient. From the summarised data, a price list based on self-costs was determined and used to pay for care of patients in Stockholm. The DRG system generates a number of points. One point can be converted into a sum of money, which changes every year because of inflation. Costs were calculated for the initial transplant period and the whole first year after HSCT. They included all in-patient and outpatient costs during this period. All costs are based on the possibility to connect all costs to each patient (CPP) and DRG estimated and based on CPP.
Statistics
We used the Mann-Whitney U-test for two-group comparison and multivariate analysis, using the forward stepwise multiple linear regression to analyse the treatments and complications associated with various costs. Variables included in the analysis were: sex (male/female), children (o18 years)/adults, diagnosis, donor (HLA-identical sibling/unrelated), disease stage, re-transplantation, nucleated cell dose, AB0 mismatch, donor age, conditioning, ATG, GVHD, rejection, bacteremia, female donor to male recipient, sinusoidal obstructive syndrome, stem cell source (BM, PBSC/cord blood), CMV infection, invasive fungal infection (IFI), use of G-CSF, home care, HC, posttransplant lymphoproliferative disorder. Factors with a P-value 40.2 in the univariate analysis were introduced into the multivariate forward stepwise analysis. Limit P-value excluding a factor from the model was P40.05.
Results
Year of transplantation and diagnosis
During the first initial treatment period, the mean cost of HSCT was h66 756 with a 95% confidence interval (95% CI) of 58 243-75 269. Corresponding figures during the first year were h141 493 (95% CI ¼ 125 019-157 967). A total of 57 patients died within 1 year after HSCT. One-year survival was 72%. Deaths within 1 year increased the costs in the univariate analysis (P ¼ 0.02). However, death within 1 year had no significant effect in the multivariate analysis (P ¼ 0.8). Therefore, death within 1 year was excluded from the multivariate analysis.
During the 5-year study period, there were some fluctuations in the 1-year costs with a tendency for a slight increase in more recent years ( Figure 1a ). There were no statistically significant differences in costs between patients with different types of diagnoses (Figure 1b) .
Patients with low-risk disease (non-malignancy and patients in first remission or first chronic phase) had a median 1-year cost of h127 014 (95% CI ¼ 103 133-150 894). There was a slight trend of increased costs in high-risk patients (beyond these stages), being h150 864 (95% CI ¼ 125 103-176 626) (P ¼ 0.07).
Donor and source of stem cells A MUD transplant was more expensive than a graft from an HLA-identical sibling (Po0.001; Figure 1c) . However, the cost of an allele-mismatched unrelated donor transplant or a one-Ag-mismatched unrelated donor transplant was not significantly different from that of the other two groups.
There was no significant difference between the sources of stem cells (BM, PBSCs or cord blood) regarding 1-year costs (Figure 1d ). However, there was a wide range of costs regarding cord blood transplants.
Conditioning
There was no difference in 1-year costs of HSCT if patients were treated with RIC or MAC (Figure 2a) . During the first treatment period, the median cost for patients undergoing RIC was h144 251 (95% CI ¼ 122 570-165 932) as opposed to h137 288 (95% CI ¼ 111 495-163 080) using MAC (P ¼ 0.37). There were similar costs in the myeloablative group in those receiving CY þ fractionated TBI and in those treated with BU and CY (P ¼ 0.80; Figure 2b ). Patients who received NMC had a significantly lower 1-year cost than RIC (P ¼ 0.01; Figure 2b ). In patients who underwent different RIC protocols, the costs were higher for those who received Flu combined with CY (P ¼ 0.001). However, this protocol was used for seven patients undergoing re-transplantation. When these patients were excluded, there was no difference in the Flu and CY groups compared with the other types of RIC conditioning.
Home care
Previous studies from our centre have shown that home care reduces the risk of acute GVHD and gives improved survival compared with treatment in a hospital. 8, 9, 23 In this study, the 1-year cost for home-care patients (n ¼ 52) was h148 142 (95% CI ¼ 112 316-183 969). This was not significantly different from that of hospital care, which was h139 188 (95% CI ¼ 120 560-157 816) (P ¼ 0.63).
G-CSF and re-transplantation G-CSF was given to 23 patients (11%) due to delayed or poor engraftment. The 1-year cost was higher than for patients who were not given G-CSF after HSCT (P ¼ 0.035; Figure 2c ).
Re-transplantation was performed in four patients because of rejection and in four patients because of relapse.
Re-transplantation was significantly associated with increased 1-year costs of HSCT, compared with first transplant (Po0.001; Figure 2d ).
Post-transplant complications
Major post-transplant complications analysed included acute GVHD, sinusoidal obstructive liver syndrome (SOS), rejection, bacteraemia, CMV infection and disease, post-transplant lymphoproliferative disorder, possible, probable and proven IFI and HC of grades 3-5. Patients with acute GVHD of grades III-IV (n ¼ 20, 10%) had increased 1-year costs (Po0.001, Figure 3a) . Of the six patients with SOS (3%), the costs during the first treatment were significantly increased compared with all other patients (P ¼ 0.003). However, their 1-year costs were not significantly different from those of all our patients, being h248 003 (95% CI ¼ 19 034-476 973) (P ¼ 0.22). Rejection occurred in 16 of the patients (8%) and was associated with increased 1-year costs: mean h251 964 during the first year (Po0.001; Figure 3b ). For patients with bacteraemia (n ¼ 52, 26%), mean 1-year costs were h172 775 (95% CI ¼ 128 207-217 342). This did not reach statistical significance compared with h130 649 (95% CI ¼ 114 686-146 611) for patients without bacteraemia (P ¼ 0.068).
CMV reactivation (PCR positivity) was diagnosed in 102 (50%) of the patients, and CMV disease was diagnosed in 14 (7%). Compared with patients without CMV infection or disease, those with PCR positivity and those with CMV disease had higher 1-year costs (Po0.001; Figure 3c ).
Post-transplant lymphoproliferative disorder was diagnosed in eight (4%) of the patients and was not associated with increased costs. Possible, proven or probable IFI occurred in 13 (6.4%) of the patients and these patients had increased 1-year costs, mean h258 421 (95% CI ¼ 86 229-805 423), compared with those without IFI (Po0.001; Figure 3d ).
Haemorrhagic cystitis (grades 3-5) requiring transfusions, was seen in 12 (6%) of the patients. Mean 1-year costs in patients with HC were h174 888 (95% CI ¼ 67 950-511 383), which was not significantly higher than in patients without HC, h139 384 (95% CI ¼ 23 866-823 431) (P ¼ 0.26).
Patients treated with MSCs had significantly higher 1-year costs than did those not given MSCs: h274 756 as opposed to h123 525 (Po0.001; Figure 3e ). No statistically significant differences in costs were seen regarding the reason for MSC treatment. Median 1-year costs for patients given MSCs for severe GVHD, HC or as engraftment support were h315 231, h182 553 and h309 900, respectively.
Costs increased with number of risk factors, especially for those with more than three risk factors (Figure 3f ).
Multivariate analysis of factors associated with increased 1-year costs of HSCT First, we performed a multivariate analysis including posttransplant complications ( Table 2 ). The following variables were found to be significantly associated with increased 1-year costs in the multivariate analysis: rejection (Po0.001), acute GVHD of grades III-IV (Po0.001), IFI (P ¼ 0.0015), CMV reactivation or disease (P ¼ 0.036) and SOS (P ¼ 0.027).
We then performed a multivariate analysis also including factors other than transplant complications in the model, such as re-transplantation, type of donor, disease stage, conditioning, G-CSF, stem-cell source, diagnosis, ATG, MSCs and age.
In this multivariate analysis, the following factors were associated with increased 1-year costs after HSCT: acute GVHD of grades III-IV (Po0.001), rejection (Po0.001), re-transplantation (P ¼ 0.001), IFI (P ¼ 0.02), MSCs (Po0.001), unrelated donor transplant (P ¼ 0.002) and G-CSF (Po0.05) ( Table 3) .
In patients without any of these risk factors (n ¼ 51), mean 1-year costs were h84 773 (95% CI ¼ 71 145-98 400). With only one of these complications seen in 91 patients, mean costs were h120 902 (95% CI ¼ 104 722-137 083). With two risk factors (n ¼ 43), mean 1-year costs were h177 186 (95% CI ¼ 145 660-208 711), and with three risk factors they were h249 775 (95% CI ¼ 166 824-332 727) (n ¼ 14). In three patients with four or five of these risk factors, mean 1-year costs were h713 412.
Discussion
In our previous cost analysis of patients who underwent HSCT in 1998 and 1999, we found that the in-patient and outpatient costs were highest during the first year. 8 Total patient costs during the subsequent 4 years were only 16% of the total 5-year in-patient and outpatient costs. Thus, in this analysis, we only included costs for the first year, which is the most costly part of HSCT. Evaluation of 5-year costs would also delay the analysis, and would require another 4 years of follow-up. In the previous study, we found that total costs during the first year were higher in patients with acute GVHD of grades III-IV, bacteraemia, SOS, prophylaxis with G-CSF, acute leukaemia and treatment in a hospital instead of at home. 8 The total 5-year costs were less with RIC, as compared with MAC, in that study. RIC is being increasingly used and enables transplantation of older patients and those with comorbidities. 14, 15, 24, 25 In recent years, more unrelated donor transplants are being performed, most patients are receiving PBSCs as a source of stem cells as opposed to BM, and home care has also been introduced on a regular basis. Cord blood transplants are only used for patients for whom an HLA-identical donor is not available. Thus, we wanted to analyse costs in the new era of HSCT using new sources of stem cells and RIC, and to evaluate their impact on costs.
Costs were increased using unrelated donors, compared with HLA-identical siblings. This was not found in our previous analysis, which may have been due to the smaller number of patients in that study (only 93). In our experience, with genome-MUDs and the use of ATG, outcome using unrelated donors is similar to that using HLA-identical siblings. 26, 27 A MUD transplant is more expensive because there are certain costs for the donor and for transportation of the transplant. In addition, MUD is more often associated with higher-risk patients and more infections, even though GVHD has not increased at our centre. 19, 27 The source of stem cells (PBSCs, BM or cord blood) had no effect on 1-year survival. Although they enhance engraftment of ANC and plts, PBSCs have not affected discharge from hospital and have a similar incidence of acute GVHD, TRM and survival to BM grafts. 28 Cord blood transplants have a high incidence of graft failure and delayed engraftment, which may increase costs. [29] [30] [31] Despite this, the costs were not higher in this cohort of patients, which may be because of the fact that only 20 patients were included in this analysis. We mainly use cord blood transplants when an HLA-identical donor is not available, and because there was a better outcome than using mismatched unrelated donors. 29 Non-myeloablative conditioning was associated with reduced costs (Figure 2a) . The reason for this is that it can be done on an outpatient basis, with a short neutropenic period and few toxic side effects. 32 Compared with MAC, RIC patients also have shorter neutropaenia and fewer toxic side effects. 15, 24, 26 Despite this, the 1-year costs were similar using RIC and MAC. Comparing different RIC conditionings, Flu combined with CY had increased costs, which is because of the fact that this was used for re-transplantation in many of our patients. Retransplantation is associated with increased costs according to this analysis (Figure 2c , Tables 2 and 3 ). Despite the costs for irradiation, MAC with or without TBI had similar 1-year costs (Figure 2a) . In a randomised study, early outcome was also found to be similar using either CY and TBI or BU and CY. 13, 33 RIC patients had similar costs to those of MAC patients, even during the early posttransplant period, despite these advantages. RIC patients often have comorbidities such as infections, and especially IFI; thus, the costs were not significantly different between RIC and MAC. Patients who receive RIC or MAC are two different populations. Many patients undergoing HSCT with RIC may not be considered for MAC because of comorbidities or high age. 15, 24, 25, 32 In previous analyses, home care was found to be associated with less acute GVHD, improved survival and reduced costs compared with hospital care. 9 In this analysis, home-care patients had the same 1-year costs as those treated in hospital, despite the fact that home care has been routine for patients living close to the hospital. On the basis of experience with home-care patients, we have also tried to use the advantages of this treatment in hospitalcare patients in more recent years. We have a nutritional team to encourage in-patients to eat better and more frequently, because GVHD has been associated with poor oral intake. 23 Furthermore, because home-care patients can take a walk whenever they want, we also allow patients isolated in the hospital to take a walk outside the hospital after 1800 hours on weekdays, and whenever they like at weekends. This increase in nutritional intake and improved exercise in hospital-care patients may have improved outcome, to approach that of home-care patients.
One of the most expensive procedures seems to be retransplantation, with a mean cost of h316 930 (Figure 2c , Table 3 ). This is to be expected, because this is a high-risk group with frequent complications after HSCT. Retransplantation is also becoming more common with NMC, RIC and cord blood transplants. 34 G-CSF prophylaxis has been reported to increase the risk of GVHD and reduce survival after HSCT. 10, 11 A study from the Center for International Blood and Marrow Transplant Research also found that G-CSF was associated with reduced survival. 35 In this analysis, G-CSF was not given as prophylaxis but only to patients with poor engraftment. G-CSF is therefore given to high-risk patients with an increased probability of rejection, a complication associated with increased costs (Figure 3b) . Therefore, the increased costs associated with G-CSF in this analysis were not due to complications induced by G-CSF, but because this treatment is used for a high-risk population.
As expected and as also found in our previous cost analyses, major complications after HSCT such as severe acute GVHD, SOS, rejection, CMV infection and IFI, significantly increase the costs. Severe acute GVHD especially is associated with high costs, because of the need for expensive immunosuppressive drugs, broadspectrum antibiotics and treatment of IFI. 36 Although there has been a slight improvement in survival in more recent years, the outcome in patients with severe acute GVHD is still poor. 21 Rejection is also associated with extremely high costs (Figure 3b , Tables 2 and 3) . Rejection is an increasing problem because of there being more NMC and RIC transplants, HLA-mismatch transplants and cord blood transplants. 34 Outcome is dismal, especially for patients who undergo re-transplantation for recurrent disease. 37, 38 CMV infection and disease was associated with increased 1-year costs, despite progress with PCR-based diagnosis and early treatment with ganciclovir or foscarnet. 39 CMV is not only associated with morbidity and mortality but also delays immune reconstitution and increases the risk of bacterial and fungal infections. 40, 41 Invasive fungal infection is a major problem after HSCT, but has declined in more recent years because of less toxic and more effective anti-fungal drugs compared with the previous golden standard, amphotericin B. 42 The poor prognosis of IFI in HSCT patients and ineffective diagnoses have necessitated the use of empirical treatment with expensive anti-fungals. [42] [43] [44] [45] In the univariate analysis, death during the first year was associated with increased costs (P ¼ 0.02). The reason for this is probably that there is a high death rate in patients with major complications, such as severe acute GVHD, rejection and IFI. These complications are expensive, regardless if the patient dies or survives. As all these complications are associated with an increased risk of death, deaths within the first year were associated with increased costs, but death was not significant in the multivariate analysis (P ¼ 0.8).
Treatment with MSCs was associated with higher 1-year costs (Po0.001). Most patients undergoing this treatment were seriously ill, with acute GVHD of grades III-IV (n ¼ 9) or severe HC (n ¼ 7), complications that are associated with increased 1-year costs. However, eight patients received MSCs as engraftment support for retransplantation or cord blood grafts. 20 These patients had costs as high as those receiving MSCs as treatment for severe GVHD. This is expected as re-transplantation is expensive. Furthermore, in patients with severe GVHD or HC, treatment with MSCs led to higher costs (P ¼ 0.02) compared with those who did not receive this treatment. New experimental procedures are first tried in patients with a poor life expectancy. MSCs were mainly used in severely ill patients not responding to any therapy. 21, 22 Haematopoietic SCT is an expensive treatment. RIC has 1-year costs that are comparable to those of MAC. Unrelated donor transplants are still more expensive than HLA-identical sibling transplants. Re-transplantation is an especially costly procedure. Otherwise, major complications such as severe acute GVHD, rejection and IFI dramatically increase the costs. Better prevention and treatment of the major complications is required to make HSCT more cost-effective.
